FTXHFirst Trust Nasdaq Pharmaceuticals ETF

Grow my money9y track recordRanked #1,885 of 2,960 in this goal

Seeks investment results that correspond generally to the price and yield of the Nasdaq US Smart Pharmaceuticals Index.

By First Trust · Launched 2016

Annual Cost

0.60%

#3,108 of 5,562 · average

Fund Size

$35M

#3,889 of 5,562 · small

Return (1Y)Goal

+40.2%

Track Record

9 years

#1,477 of 5,562 · established

Performance

Total-return NAV · USD

Growth of $10,000

$14,013+40.1%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Multi cap

Strategy

Index tracking

Sector

Health care

Focus

Biotech & Genomics

Index tracked

Nasdaq US Smart Pharmaceuticals Index

What it actually holds

By weight

Concentration

Top 10 holdings = 55.3% of fundmoderately concentrated

Merck & Co Inc

7.7%

Johnson & Johnson

7.2%

Bristol-Myers Squibb Co

7.0%

AbbVie Inc

6.7%

Pfizer Inc

6.2%

Eli Lilly & Co

4.5%

Cardinal Health Inc

4.3%

Regeneron Pharmaceuticals Inc

4.1%

Biogen Inc

4.0%

Viatris Inc

3.6%

Asset allocation

Stocks

99.9%

Cash

0.1%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

17.1%Moderate

Year-on-year price swings

Max drawdown

-32.1%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.55Decent risk-adjusted returns

Sortino (3Y)

0.79Moderate downside risk

Where to buy

Listing

Exchange: NASDAQ Global Select Market

Full fund details

Objective: Seeks investment results that correspond generally to the price and yield of the Nasdaq US Smart Pharmaceuticals Index.
Strategy: Invests primarily in securities that comprise the Nasdaq US Smart Pharmaceuticals Index, aiming to replicate its performance. The Index includes top factor-ranked U.S. pharmaceutical and biotechnology companies, rebalanced semi-annually.
Inception date: September 20, 2016
Fund family: First Trust